New York, January 5, 2026, 5:47 PM ET — After-hours
- Eli Lilly shares were down 3.6% in late trading after sliding during Monday’s session.
- The move followed Novo Nordisk’s U.S. rollout of a pill version of Wegovy, shifting attention to pricing and market share in obesity drugs.
- Investors’ next checkpoints include management commentary at the J.P. Morgan Healthcare Conference and Lilly’s upcoming earnings call.
Eli Lilly and Co shares fell on Monday and were last down 3.6% at $1,041.51 in after-hours trading. The stock weakened as rival Novo Nordisk began rolling out a pill version of its Wegovy weight-loss drug in the United States.
The drop matters because investors have priced Lilly as a long-duration obesity winner, with expectations anchored to rapid growth in demand and tight supply. Any new sign that the market is shifting toward cheaper oral options can force a reset in assumptions about pricing power.
GLP-1 drugs, which target hormones involved in appetite and blood sugar control, have transformed obesity treatment and pushed the sector into the center of equity markets. The next leg of competition is moving into “self-pay” channels, where patients pay out of pocket rather than through insurance.
Novo said it began selling a once-daily Wegovy pill in the United States on Monday, pricing low doses at $149 per month for self-paying patients, with higher doses priced up to $299 and the 4-mg dose set to rise to $199 from April 15. The drugmaker said it will distribute through CVS and Costco and via telehealth partners, with additional doses available by the end of this week. Lilly has said it expects an FDA decision in March for its own obesity pill and would cap repeat-cash pricing for higher doses at $399; both companies also agreed to offer $149 starter doses under a White House deal tied to a planned TrumpRx site.
Novo’s U.S.-listed shares were up 5.2% late Monday, underscoring investor enthusiasm for the pill launch even as Lilly slipped. The Health Care Select Sector SPDR Fund was down 0.3%, while the SPDR S&P Biotech ETF fell 1.1%.
The broader tape was risk-on, with Wall Street ending higher as energy and financial shares led gains after a U.S. strike in Venezuela pushed oil-linked stocks up, a Reuters report said. That rotation left defensive pockets, including parts of healthcare, lagging.
Lilly’s slide left the stock probing its near-term floor after it traded down to around $1,034 earlier in the session. Traders will watch whether it can reclaim the day’s highs near $1,085, while a break lower brings the round-number $1,000 level into focus.
But the push into cash-pay programs cuts both ways: broader access can widen the market, while faster discounting can compress margins if it becomes the default pricing model. GoodRx Chief Executive Wendy Barnes said the platform was leaning into “transparent cash pricing” and “broad pharmacy availability” as Wegovy pill access expands, language that points to intensifying price visibility across the category. Business Wire
For Lilly investors, the key question is whether the market is expanding fast enough to absorb new entrants without forcing a deeper price reset, and whether management can keep prescriptions growing while defending profitability. Policy risk around drug pricing remains a swing factor for sentiment in the group.
The next catalysts come quickly: Lilly’s investor site lists CEO David Ricks speaking at the J.P. Morgan Healthcare Conference on Jan. 13, followed by the company’s Q4 2025 earnings call on Feb. 4, events likely to shape expectations for obesity-drug pricing, supply and the oral pipeline.
